← All trials
NCT02506933
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 5, 2015
- Primary completion
- Apr 1, 2018
- Completion date
- Apr 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 115
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- City of Hope National Medical CenterLead sponsor
- National Cancer Institute (NCI)Collaborator
- Fortress BiotechCollaborator
- City of Hope National Medical CenterOverall official - principal investigator
Drugs studied
Indications studied
- Lymphadenopathy
- Cytomegalovirus Infections
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Leukemia, Lymphocytic, Chronic, B-Cell
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Primary Myelofibrosis
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.